dyslipidemia in ms

Upload: gilang-kusdinar

Post on 03-Mar-2018

222 views

Category:

Documents


0 download

TRANSCRIPT

  • 7/26/2019 Dyslipidemia in MS

    1/54

    Presenter: Gilang KusdinarModerator: Dr.Maimun Z.A., MKes, Sp.PK

    1

    Tropic infection-ase Discussion

    !ig" #e$el Protein of S% &D'slipidemia

    in patient (it" Multiple Sclerosis

  • 7/26/2019 Dyslipidemia in MS

    2/54

    Summary of Database

    Mrs. )* ++ 'ears old* !ospitalied: 1-1-/1+* M0 1/23++4

    Chief complaint: Tetraparesis 5(ea6ness on + e7tremities8

    T"e patient suddenl' felt (ea6ness on legs + da's 9efore

    admission 5(orsening t"an 9efore8 and da's 9efore

    admission, "er arms and legs "ad (ea6ness and num9.

    S"e also felt nec6 pain 9ut didnt radiated.

    ;o complaint on "er urination and passed stool.

    S"e felt decrease of appetite and 9od' (eig"t since 1 mont"

    ago 5

  • 7/26/2019 Dyslipidemia in MS

    3/54

    Past medical illness: Parese in "er left e7tremit' 5+ mont"s

    ago8

    "ospitalied 11 da's (it"outclinical impro$ed.

    !T & Dia9etes denied!istor' of treatment: Drug 5from general practitioner8 +

    mont"s

    Acupuncture3

  • 7/26/2019 Dyslipidemia in MS

    4/54

    Physical Examination

    General Appearance: moderately ill GCS 456!:4" #$% &: '56 cm

    >italSign

    ?P /*2/ Pulse: 11/ 7*m

    00: +7*mnt

    Ta7 32,2/

    !ead on@uncti$a anemis 5-8 S6lera icteric 5-8;ec6 #'mp"adenopati 5-8, >P 0B/ cm!C,pain 5B8

    T"ora7 or ctus in$isi9le, palpa9le in M# 5S8 >#!M E ictus 0!M E Sternal line DS1-Ssingle, reguler

    Pulmo Simetric, Stem %remitus D F SAus6ultasi : 0onc"i 5-8, )"eeing 5-8

    A9domen

    Soe, ?S 5B8 ;, li$er span = cm, lien unpalpa9le

    H7tremit )arm acral, anemis 5-8, edema 5-8 M + +

    +

  • 7/26/2019 Dyslipidemia in MS

    5/54

    (aboratory )esults

    CC '*+'"+",'4 "-+'"+",'4 )eference

    !9 1, 11, g*dl 11,+ J 14,1

    Hritroc'te +,23 +,+/ 1/2*l +,/ J 4,4

    !ct 3,/ 32,1/ L +/ J +

    M> =1,/ =,// f# =/ - 3

    M! ,+/ ,// pg - 31

    0D) 14,3/ 1+,1 L 11.4 - 1+.4

    )? +/ 1.==/ *# +3// - 1/3//

    P#T 43+./// 4+./// *# 1+.///-++.///

    HS0 2=

    Di count5Ho*?a*St*Seg* #'*Mo8

    2*-*-*+*3=* 1*-*-*=/*13*2 L /-+ * /-1* 3-4*41-2* 4-33* -4

    4

  • 7/26/2019 Dyslipidemia in MS

    6/54

    (aboratory )esults1-1 ",+'" "'+'" ""+'" 0eference

    0?S =1 N // mg*dl

    %?G 2 24 2/ J 1// mg*d#

    ?G " pp 112 N 13/ mg*dl

    Oreum 1, 11,+/ 1,// 12,2J+=,4 mg*dl

    reatinin /,4= /,44 /,4+ N1, mg*dl

    Oric acid +, 3,1 ,+ J 4, mg*d#

    SGCT 1= 13 12 12 / J +/ mO*dl

    SGPT 1 1= 1= / J +1 mO*dl

    Total"ol.

    1=+ 34 N // mg*d#

    TG 13/ 131 N 14/ mg*d#

    !D#-"ol 34 32 N 32 mg*d#

    #D#-"ol 11+ 1=1 N 1// mg*d#

    Al9umin 3,/ 3, 3,4 J 4,4 g*d#

    2

  • 7/26/2019 Dyslipidemia in MS

    7/54

    Electrolyte )esults

    1-1-1+ ",+'"+'4

    ""+'"+'4

    0eference

    ;a 13= 13+ 133 132-1+4mmol* #

    K 3,= 3, +,3 3,4-4,/mmol* #

    l 1/ 114 11 =-1/2mmol*#

  • 7/26/2019 Dyslipidemia in MS

    8/54

    !emostasis 0esult

    /*1*1+ *1*1+

    PPT 5sec8 11,1 13,+/

    ontrol 5sec8 11.+ 1./

    ;0 /.2 1.14

    APTT ./ 34.3/

    ontrol 5sec8 +.3 4.3

    onclusion PPT and APTT(it"in normal

    limit

    PPT and APTT(it"in normal

    limit

  • 7/26/2019 Dyslipidemia in MS

    9/54

    3*1*1+ 0eference

    larit' &colour

    lear -ello(is"

    p! 2,/ +,4-=,/

    SG 1,/4 1,//4-1,/3/

    Glucose ;egati$e -5negati$e8

    Protein ;egati$e -5negati$e8

    Keton Trace -5negati$e8

    ?iliru9in ;egati$e -5negati$e8

    Oro9ilinogen

    ;egati$e -5negati$e

    8

    .rinalysis

    Microscopic

    )ef/

    +/7Hr't"roc't

    eHumorp"icD'smorp"ic

    ,

    --

    Q 3 !P%

    #eucoc'te 1+2,= Q 4 !P%

    r'stal -3 3

  • 7/26/2019 Dyslipidemia in MS

    10/54

    (01.2) CE)E)2SP03A(A3A(S0S3*1*1+ 3*1*1+

    Macroscopic

    olour lot Appearance

    lear;egati$elear

    lear;egati$elear

    Microscopic Hr'troc'te

    count #eucoc'te count PM; M;

    3// *R#

    1/ *R#/ L1//L

    +// *R#

    1/ *R#/ L1// L

    "emistr' Protein Total Glucose #D!

    1/1,2 g*d#/ mg*d#3 O*#

    1/=2,/ g*d#2= mg*d#+4 O*#

    Special Test

    ;onne Pand

    Positi$ePositi$e

    Positi$ePositi$e

    1/

  • 7/26/2019 Dyslipidemia in MS

    11/54

    Cerical )0 7"4+'"+",'48:

    ntramedullar multiple lesion at le$el$erte9rae cer$ical 1-, 3-+ and 4-2,susp. multiple sclerosis

    !;P9ulging t'pe at le$el > 3-+ and +-4

    Discus and corpus degeneration of -T1 Spond'losiscer$icalis and straig"t cer$icalis

    Chest 9+)ay 7'+'"+",'48:

    nIltrate and ca$it' in lo9us superior 5D8 onclusion: susp. spesiIc process 5T?

    pulmonal8 DD pneumonia

    E;G 7'+'"+",'48: S'nus r't"m, !0 =7*m

  • 7/26/2019 Dyslipidemia in MS

    12/54

    Data 0nterpretation

    #a9orator' results s"o(ed leu6oc'tosis,t"rom9oc'tosis, ele$ated total c"olesterol,lo(er !D#-c"olesterol, ele$ated #D#-

    c"olesterol, ele$ated total protein and positi$enonne-pand' in #S anal'sis, 6etonuria,nitrituria and leu6oc'turia.

    %rom "istor' ta6ing, p"'sical e7amination,

    la9orator' results and ot"er e7aminationsindicated Multiple Sclerosis DD T? cer$icalis(it" S0S susp sepsis, and d'slipidemia.

    Suggestion: Protein electrop"oresis of

    S%,urine culture, %A?, sputum culture and 1

  • 7/26/2019 Dyslipidemia in MS

    13/54

    Discussion

    1

  • 7/26/2019 Dyslipidemia in MS

    14/54

    ultiple Sclerosis

    Multiple sclerosis 5MS8 is aneuroinammator' andneurodegenerati$e disease t"at results in

    damage to m'elin s"eat"s and a7ons int"e central ner$ous s'stem and ("ic"preferentiall' aects 'oung adults.

    T"is disease is c"aracteried (it"multiple neurological disorderss'mptoms including $ision, sensor', 9od'(ea6ness, diculties in (al6ing and

    a9dominal and 9ladder disorders due toSerum lipid proIles are associated (it" disa9ilit' and M0 outcomes inmultiple sclerosis

  • 7/26/2019 Dyslipidemia in MS

    15/54

    MS can 9e clinicall' di$ided into t"reedierent ma@or forms: relapsingremitting 500MS8, secondar' progressi$e5SPMS8 and primar' progressi$e 5PPMS8,respecti$el'.

    n addition, t"e clinicall' isolated

    s'ndrome 5S8 "as 9een descri9ed in("ic" a single episode of t"e s'mptomsof 00MS patients ma' 9e a Irstindication of MS.

  • 7/26/2019 Dyslipidemia in MS

    16/54

    urrent diagnosis relies on clinicale7amination supported 9' la9orator'in$estigations including Magnetic 0esonance

    maging 5M08 to $isualise lesions, and S%9ioc"emistr' measurements t"at includeassessment of t"e oligoclonal 9and5s8 of gGand 9arrier inde7.

    S% protein electrop"oresis is for t"e detectionof oligoclonal 9ands representinginammation (it"in t"e ;S.

    T"e 9ands are located in t"e gamma region of

    t"e protein electrop"oresis, indicatingMultiple Sclerosis: dentiIcation And linical H$aluation Cf

    ;o$el S% ?iomar6ers, an Ctter$ald Ht Al, S(eden. ournal Cf

  • 7/26/2019 Dyslipidemia in MS

    17/54

    T"e S%*serum al9umin inde7 is calculatedafter determining t"e concentration of S%al9umin in mg*d# and t"e serum concentration

    in g*d#. T"e formula used is as follo(s:

    An inde7 $alue less t"an represents an intact9lood 9rain 9arrier. T"e inde7 increases relati$eto t"e amount of damage to t"e 9arrier.

    Strasinger SK & #oreno M, Orinal'sis and ?od' %luids,4t" ed //=

  • 7/26/2019 Dyslipidemia in MS

    18/54

    1=

    Susp. Multiple

    sclerosis DD T?

    T"eor' Patient

    nammator',

    dem'elinating andneurodegenerati$edisease aect 'oungadult.

    Disorders of $ision,sensor', 9od'(ea6ness, diculties in(al6ing and a9dominaland 9ladder

    d'sfunction.Protein 5S%8 Indings5ele$ated gG inde7 or or more oligoclonal

    9ands8M0: U of + lesions in

    %emale, ++ '.o

    TetraparesisPatient cant (al6ing;um9ness in +e7tremities

    ;ec6 painT"rom9oc'tosisM0: ntramedullarmultiple lesion at le$el>. er$i$al

    S%: M; 1//L, "ig"le$el of protein andpositi$e nonne-pand'.

    Su$$estion:Protein

    electrop"oresis of

  • 7/26/2019 Dyslipidemia in MS

    19/54

    S0)S susp/ sepsis in this patient Sepsis and Septic shoc# associated ?ith 2DSbased on ACCP%SCC Consensus Conference 7.SA '@@"8

    S'stemicnammator'

    0esponse S'ndrome5S0S8

    * V clinical signs 9elo(:Temp V 3=o or N 32o !eart rate V /7*mTac"'pneu 500 V/7*m 8 or

    "'per$entilation 5PaC N 3 mm!g8 )? V 1,///*Rl or N +///*Rl or V 1/L

    immature neutrop"il 59ands8

    Sepsis 5S0S BSource of infection8

    T(o or more S0S criteria (it" suspectedor present source of infection.

    Se$ere Sepsis Sepsis (it" organ d'sfunction,"'potension or "'poperfusion 5not limitedto t"e lactic acidosis, oliguria, altered

    mental status8, S?P N / or S?P drop U +/mm!g of normal.

    Septic S"oc6 Se$ere sepsis (it" "'potension despiteadeWuate uid resuscitation and"'poperfusion.

    Multiple Crgan H$idence of U organs falling

    2

  • 7/26/2019 Dyslipidemia in MS

    27/54

  • 7/26/2019 Dyslipidemia in MS

    28/54

    T"ere is complete agreement t"at isoelectricfocusing 5H%8 on agarose gels follo(ed 9'

    immuno9lotting s"ould 9e t"e Xgold standardYfor detecting t"e presence of oligoclonal 9ands.

    Ct"er met"ods suc" as pol'acr'lamide gelcom9ined (it" H% and sil$er staining of

    proteins mig"t "a$e pro$en useful in t"e past,9ut t"e' lac6 speciIcit' for gG and, "ence, arenot supported 9' consensus.

    A direct comparison of t"e accurac' of t"e tec"niWues is gi$en in =able '/

  • 7/26/2019 Dyslipidemia in MS

    29/54

  • 7/26/2019 Dyslipidemia in MS

    30/54

  • 7/26/2019 Dyslipidemia in MS

    31/54

  • 7/26/2019 Dyslipidemia in MS

    32/54

    andidate 9iomar6ers t"at signiIcantincreases in t"e S% le$els: alp"a-1antic"'motr'psin 5A1A8, alp"a-1macroglo9ulin 5AMG8 and I9ulin 1.

    Anot"er 9iomar6er t"at increases in t"eS%: protein contactin 1, fetuin A, $itamin

    D 9inding protein and angiotensinogen5A;GT8.

    mmunoassa'

    Measurement

  • 7/26/2019 Dyslipidemia in MS

    33/54

    Strasinger SK & #oreno M, Orinal'sis and ?od' %luids,4t" ed //=

  • 7/26/2019 Dyslipidemia in MS

    34/54

    Strasinger SK oreno M,

    Orinal'sis and?od' %luids, 4t"

    ed, //=

  • 7/26/2019 Dyslipidemia in MS

    35/54

    Strasinger SK oreno M,

    Orinal'sis and?od' %luids, 4t"

    ed, //=

  • 7/26/2019 Dyslipidemia in MS

    36/54

    ES)

    Pisets6' DS. #a9orator' testing in t"e r"eumatic diseases. n: Goldman #, Sc"afer A,eds. Goldman's Cecil Medicine. +t" ed. P"iladelp"ia, PA: Saunders Hlse$ier /11:c"ap 24.

  • 7/26/2019 Dyslipidemia in MS

    37/54

  • 7/26/2019 Dyslipidemia in MS

    38/54

    Multiple Sclerosis: dentiIcation And linical H$aluation Cf

    ;o$el S% ?iomar6ers, an Ctter$ald Ht Al, S(eden. ournal Cf

  • 7/26/2019 Dyslipidemia in MS

    39/54

  • 7/26/2019 Dyslipidemia in MS

    40/54

  • 7/26/2019 Dyslipidemia in MS

    41/54

    Strasinger SK & #oreno M, Orinal'sis and ?od' %luids,4t" ed //=

  • 7/26/2019 Dyslipidemia in MS

    42/54

  • 7/26/2019 Dyslipidemia in MS

    43/54

  • 7/26/2019 Dyslipidemia in MS

    44/54

    Strasinger SK oreno M,

    Orinal'sis and?od' %luids, 4t"

    ed, //=

  • 7/26/2019 Dyslipidemia in MS

    45/54

  • 7/26/2019 Dyslipidemia in MS

    46/54

  • 7/26/2019 Dyslipidemia in MS

    47/54

    Strasinger SK & #oreno M, Orinal'sis and ?od' %luids,4t" ed //=

  • 7/26/2019 Dyslipidemia in MS

    48/54

    Strasinger SK & #oreno M, Orinal'sis and ?od' %luids,4t" ed //=

  • 7/26/2019 Dyslipidemia in MS

    49/54

    Strasin er SK & #oreno M Orinal sis and ?od %luids

  • 7/26/2019 Dyslipidemia in MS

    50/54

  • 7/26/2019 Dyslipidemia in MS

    51/54

    Strasinger SK & #oreno M, Orinal'sis and ?od' %luids,4t" ed //=

  • 7/26/2019 Dyslipidemia in MS

    52/54

    =ype 0 cell+mediated disease7syndrome> autoanti$en and conseBuence8

  • 7/26/2019 Dyslipidemia in MS

    53/54

  • 7/26/2019 Dyslipidemia in MS

    54/54